3-(3-hydroxy-propyl)-pentane-2,4-dione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-(3-hydroxy-propyl)-pentane-2,4-dione
• 英文别名: 3-(3-Hydroxypropyl)pentane-2,4-dione；3-(3-hydroxypropyl)pentane-2,4-dione
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: NBMOUDCRMOGZPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-hydroxy-propyl)-pentane-2,4-dione 在 盐酸 、 水 、 三溴化磷 、 potassium carbonate 、 一水合肼 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 AG10
  参考文献：
  名称：

  [EN] PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF
  [FR] PROCÉDÉS DE PRÉPARATION D'AG-10, DE SES INTERMÉDIAIRES ET DE SELS CORRESPONDANTS

  摘要：

  本文提供了改进的工艺，用于制备化合物IX（AG-10）。本文还提供了化学上可接受的盐形式（I）和（lb）以及结晶型式的化合物IX（AG-10）。本文描述的工艺提供了改进的产量和效率，而化学上可接受的盐和结晶形式提供了意想不到的药代动力学特性。阅读本说明书其余部分后，专业人士将会发现本公开内容的其他特点和方面。

  公开号：

  WO2018151815A1
• 作为产物：
  描述：

  1,3-二溴丙烷 、 乙酰丙酮 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 40.0h， 以102 g的产率得到3-(3-hydroxy-propyl)-pentane-2,4-dione
  参考文献：
  名称：

  [EN] PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF
  [FR] PROCÉDÉS DE PRÉPARATION D'AG-10, DE SES INTERMÉDIAIRES ET DE SELS CORRESPONDANTS

  摘要：

  本文提供了改进的工艺，用于制备化合物IX（AG-10）。本文还提供了化学上可接受的盐形式（I）和（lb）以及结晶型式的化合物IX（AG-10）。本文描述的工艺提供了改进的产量和效率，而化学上可接受的盐和结晶形式提供了意想不到的药代动力学特性。阅读本说明书其余部分后，专业人士将会发现本公开内容的其他特点和方面。

  公开号：

  WO2018151815A1

文献信息

• PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF
  申请人：Eidos Therapeutics, Inc.

  公开号：US20200247756A1

  公开（公告）日：2020-08-06

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.

  本文提供了制备化合物IX（AG-10）的改进工艺。还提供了公式I和公式Ibas的药学上可接受的盐，以及公式IX（AG-10）的晶体类型。所述工艺提供了更高的产量和效率，而药学上可接受的盐和晶体形式则提供了意外的药代动力学特性。在阅读本说明书的其余部分后，本公开的其他特征和方面将对技术人员显而易见。
• Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
  申请人：Miao Zhenwei

  公开号：US20090240029A1

  公开（公告）日：2009-09-24

  Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one heterocycle, aldol-based, dicarbonyl, and/or diamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one heterocycle, aldol-based, dicarbonyl, and/or diamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

  本文披露了非天然氨基酸和多肽，其中包括至少一个非天然氨基酸，以及制备这种非天然氨基酸和多肽的方法。这些非天然氨基酸本身或作为多肽的一部分，可以包括各种可能的功能，但通常至少具有一个杂环，醛缩基，二羰基和/或二胺基团。本文还披露了经翻译后进一步修饰的非天然氨基酸多肽，以及实现这种修饰的方法和纯化这种多肽的方法。通常，修饰后的非天然氨基酸多肽包括至少一个杂环，醛缩基，二羰基和/或二胺基团。此外，还披露了使用这种非天然氨基酸多肽和经修饰的非天然氨基酸多肽的方法，包括治疗，诊断和其他生物技术用途。
• Processes for preparing AG-10, its intermediates, and salts thereof
  申请人：Eidos Therapeutics, Inc.

  公开号：US11078162B2

  公开（公告）日：2021-08-03

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.

  本文提供了制备式 IX（AG-10）化合物的改进工艺。本文还提供了式 I 和式 Ib 的药学上可接受的盐。 以及式 IX（AG-10）的结晶类型。本文所述的工艺提高了产量和效率，而药学上可接受的盐类和结晶形式提供了意想不到的药代动力学特性。本领域技术人员在阅读本说明书的其余部分时，会发现本公开内容的其他特征和方面。
• Processes For Preparing AG-10, Its Intermediates, and Salts Thereof
  申请人：Eidos Therapeutics, Inc.

  公开号：US20180237396A1

  公开（公告）日：2018-08-23

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.
• [EN] PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION D'AG-10, DE SES INTERMÉDIAIRES ET DE SELS CORRESPONDANTS
  申请人：EIDOS THERAPEUTICS INC

  公开号：WO2018151815A1

  公开（公告）日：2018-08-23

  Provided herein are improved processes for the preparation of a compound of Formula IX (AG- 10). Also provided herein are pharmaceutically acceptable salts of Formula (I) and Formula (lb) as well as crystalline types of Formula IX (AG- 10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.

  本文提供了改进的工艺，用于制备化合物IX（AG-10）。本文还提供了化学上可接受的盐形式（I）和（lb）以及结晶型式的化合物IX（AG-10）。本文描述的工艺提供了改进的产量和效率，而化学上可接受的盐和结晶形式提供了意想不到的药代动力学特性。阅读本说明书其余部分后，专业人士将会发现本公开内容的其他特点和方面。